Rumyana STOYANOVA, Desislav TOMOV, Dimitar DELKOV, Lyubka YOANIDU, Ivan DECHEV, Yordanka UZUNOVA

Oncometabolites in urine – a new opportunity for detection and prognosis of the clinical progress of verified prostate cancer-a pilot study

Background/aim: Oncometabolites provide a new approach towards the diagnostics and prognosis of the clinical progress of prostate cancer (PCa). This study is about the diagnostic and predictive value of a panel of urinary oncometabolites (ethanolamine, kynurenine, β-alanine, α-alanine, leucine, isoleucine, γ-aminobutyric acid, and sarcosine) and correlation with prostate-specific antigen (PSA) and Gleason score in patients diagnosed with prostate cancer. Materials and methods: The participants in this cross-sectional study were divided into PCa group (101 patients who matched the including criteria, average age 71) and control group (52 individuals, with no evidence of malignancy, without oncological and other chronic diseases, and without prostate gland pathology, average age 40). The criteria to be included in the PCa group were as follows: i) being diagnosed with prostate cancer, based on digital rectal examination (DRE), prostate ultrasound investigation, or biopsy; ii) not being subjected to a surgical or any other treatment; iii) not having any other concomitant oncological diseases, renal failure, diabetes mellitus. The urinary concentration of the selected metabolites was established through high-performance liquid chromatography with tandem mass spectrometry detection (HPLC-MS/MS). Results: The comparison of both groups established a significantly different elevated concentration of ethanolamine, sarcosine and kynurenine, and a significantly different decreased concentration of β-alanine and isoleucine in PCa group. No changes of the values were detected in the PCa group with PSA levels below and above 10 ng/mL and Gleason score below and above 6 (p > 0.05). To test whether combination of several variables is more powerful in discriminating between PCa and control group multiple logistic regression analysis was performed. A model including ethanolamine, sarcosine, kynurenine, β-alanine, and isoleucine demonstrated negative predictive power (NPP) 76.2% and positive predictive power (PPP) 81.8%. Conclusion: Urinary concentrations of ethanolamine, sarcosine, kynurenine, β-alanine, and isoleucine in PCa group differ significantly from that of control group. New expanded population studies are needed to discuss our results.

PDF

___

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer 2015; 136 (5): e359-e386. doi: 10.1002/ijc.29210
2. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. European Urology 2017; 71 (4): 618-629. doi: 10.1016/j. eururo.2016.08.003
3. Rigau M, Olivan M, Garcia M, Sequeiros T, Montes M et al. The present and future of prostate cancer urine biomarkers, International Journal of Molecular Sciences 2013; 14 (6): 12620-12649. doi: 10.3390/ijms140612620
4. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. Journal of Clinical Oncology 2011; 29 (16): 2185-2190. doi: 10.1200/JCO.2010.32.8112
5. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. Journal of Urology 2011; 185 (3): 869- 875. doi: 10.1016/j.juro.2010.10.057
6. Trock BJ. Application of metabolomics to prostate cancer. Urologic Oncology: Seminars and Original Investigations 2011; 29 (5): 572-581. doi: 10.1016/j.urolonc.2011.08.002
7. Aboud OA, Weiss RH. New opportunities from the cancer metabolome. Clinical Chemistry 2013; 59 (1): 138-146. doi: 10.1373/clinchem.2012.184598
8. Fernández-Peralbo MA, Gómez-Gómez E, Calderón-Santiago M, Carrasco-Valiente J, Ruiz-García J et al. Prostate cancer patients–negative biopsy controls discrimination by untargeted metabolomics analysis of urine by LC-QTOF: Upstream information on other omics. Scientific Reports 2016; 6: 38243. doi: 10.1038/srep38243
9. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 910-914. doi: 10.1038/nature07762
10. Colleselli D, Stenzl A, Schwentner C. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumors. European Urology 2010; 58: e51 doi: 10.1016/j.eururo.2010.08.017
11. Cao DL, Ye DW, Zhu Y, Zhang HL, Wang YX et al. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine. Prostate Cancer and Prostatic Diseases 2011; 14 (2): 166-172. doi: 10.1038/pcan.2011.2
12. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A et al., Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumors. European Urology 2010; 58 (1): 12-18. doi: 10.1016/j.eururo.2010.01.035
13. Pérez-Rambla C, Puchades-Carrasco L, García-Flores M, RubioBriones J, López-Guerrero JA et al. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia. Metabolomics 2017; 13 (5): 52. doi: 10.1007/s11306-017-1194-y
14. Lima AR, Pinto J, Amaro F, Bastos ML, Carvalho M et al. Advances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics. Metabolites 2021; 11 (3): 181. doi: 10.3390/metabo11030181
15. Moore JF, Sharer JD. Methods for quantitative creatinine determination. Current Protocols in Human Genetics 2017; 6 (93): A.3O.1-A.3O.7. doi: 10.1002/cphg.38
16. Jiang Y, Cheng X, Wang C, Ma Y. Quantitative determination of sarcosine and related compounds in urinary samples by liquid chromatography with tandem mass spectrometry. Analytical Chemistry 2010; 82 (21): 9022-9027. doi: 10.1021/ac1019914
17. Gkotsos G, Virgiliou C, Lagoudaki I, Sardeli C, Raikos N et al. The role of sarcosine, uracil, and kynurenic acid metabolism in urine for diagnosis and progression monitoring of prostate cancer. Metabolites 2017; 7 (1): 9. doi: 10.3390/metabo7010009
18. Dereziński P, Klupczynska A, Sawicki W, Pałka JA, Kokot ZJ. Amino acid profiles of serum and urine in search for prostate cancer biomarkers: a pilot study. International Journal of Medical Sciences 2017; 14 (1): 1–12. doi: 10.7150/ijms.15783
19. Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K et al. Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magnetic Resonance in Medicine 2008; 60 (1): 33–40. doi: 10.1002/mrm.21647
20. Meyer TE, Fox SD, Issaq HJ, Xu X, Chu LW et al. A reproducible and high-throughput HPLC/MS method to separate sarcosine from α- and β-alanine and to quantify sarcosine in human serum and urine. Analitical Chemistry 2011; 83(14): 5735-40. doi: 10.1021/ac201003r